Clinical trials: Liraglutide
Type 2 Diabetes Mellitus
GLP-1/Basal Insulin Combination Therapy
This is a real-world, pre-post observational study from an ambulatory endocrinology practice which will determine the effectiveness and safety of the addition of glucagon-like peptide-1(GLP-1) agonist therapy (weekly exenatide…
- Trial name
- NCT02895672
- Testing
- GLP-1 therapy
- Volunteers
- 150 people
- Sponsor
- Albany College of Pharmacy and Health Sciences
Diabetes, Diabetes Mellitus, Type 2
A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.
- Trial name
- NCT02077946
- Testing
- liraglutide, sitagliptin
- Where
- Sweden
- Volunteers
- 1,059 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates
The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks.
- Trial name
- INTENSIFY (NCT03823339)
- Testing
- Insulin degludec/liraglutide
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Safety and Tolerability of NN9068 in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068.
- Trial name
- NCT00983021
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ I Japan (NCT02607306)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 76 sites in Japan
- Volunteers
- 819 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal.
- Trial name
- NCT04466566
- Testing
- Saline, Exendin-9,39, Liraglutide
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight…
- Trial name
- NCT01029886
- Testing
- exenatide once weekly, liraglutide
- Where
- 108 sites in Argentina, Australia and 19 more
- Volunteers
- 912 people
- Sponsor
- AstraZeneca
Obesity
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Observational studies suggest that bariatric surgery is the most effective intervention for weight loss. Comparative effectiveness of Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) demonstrate that RYGB is…
- Trial name
- NCT03115424
- Testing
- Saxenda, RYGB
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Type 2 Diabetes
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
Background: The pill metformin treats diabetes. But it does not work for all youth, especially African-Americans. The injectable Liraglutide treats type 2 diabetes in adults.
- Trial name
- NCT02960659
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in…
- Trial name
- NCT02889510
- Testing
- liraglutide
- Where
- 6 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Lecube, Albert, M.D.
Type 2 Diabetes Mellitus
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cognitive function in patients…
- Trial name
- NCT05360147
- Testing
- Liraglutide, Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Third Military Medical University
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Hyperglycemia, Chronic Heart Failure
The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus
Type 2 diabetes (T2D) is a major risk factor of chronic heart failure (CHF). Glycemic control in patients with the combination of T2D and CHF is complicated and the currently available treatments have proven to be inadequate in…
- Trial name
- NCT01472640
- Testing
- liraglutide
- Where
- 4 sites in Denmark
- Volunteers
- 240 people
- Sponsor
- Flyvbjerg, Allan, DMSc
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT01572740
- Testing
- liraglutide, insulin
- Where
- 23 sites in Japan
- Volunteers
- 257 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.
- Trial name
- NCT01508923
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- Novo Nordisk A/S
Ischemic Stroke, Transient Ischemic Attack
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
- Trial name
- LAMP (NCT03948347)
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 1,708 people
- Sponsor
- First Affiliated Hospital of Jinan University
Metabolism and Nutrition Disorder, Obesity
Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors
This trial is conducted in Europe. The aim of this trial is to investigate bioequivalence between single-dose liraglutide administered subcutaneously with two different pen-injectors.
- Trial name
- NCT02207348
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Polycystic Ovary Syndrome, Obesity
Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug.
- Trial name
- NCT02909933
- Testing
- liraglutide, metformin and liraglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial…
- Trial name
- NCT01517555
- Testing
- liraglutide, paracetamol
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2, Metabolic Syndrome
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
The most important cause of mortality amongst DM2 patients is cardiovascular disease. An early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction.
- Conditions
- Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction
- Trial name
- MAGNA VICTORIA (NCT01761318)
- Testing
- Liraglutide
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center